Is there a role for herbal medicine in the treatment of pancreatic cancer?

Journal of the Pancreas

Volumn 9, Issue 4, 2008, Pages 403-407

  Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Antineoplastic agents; Capecitabine; Chinese herbal; Chinese traditional; Curcumin; Drugs; Medicine; NF kappa B; Pancreas; Pancreatic neoplasms; PHY 906; Phytogenic

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CHINESE DRUG; CURCUMIN; GAMMA INTERFERON; GEMCITABINE; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PHY 906; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; HUMAN; LIVER PROTECTION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREAS CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CURCUMIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; FLUOROURACIL; HUMANS; MEDICINE, HERBAL; MULTICENTER STUDIES AS TOPIC; PANCREATIC NEOPLASMS; PLANT PREPARATIONS;

EID: 48949099568     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 2008; 99:836-42.
2. Epelbaum R, Vizel B, Bar-Sela G. Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 26: 2008 (May 20, suppl; abstr 15619).
3. Hoimes CJ, Lamb L, Ruta S, Elligers K, Mezes M, Grant N, et al. A phase I/II study of PHY906 plus capecitabine (CAP) in patients (pts) with advanced pancreatic cancer (APC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 15538).
4. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65:1631-52.
5. Shu JC, Zhao JR, Yang DH, et al. Effect of curcumin on proliferation and apoptosis of hepatic stellate cell line. Chin J Dig 2004; 24:282-4.
6. Zheng S, Chen A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 2004; 384:149-57.
7. Park SD, Jung JH, Lee HW, Kwon YM, Chung KH, Kim MG, Kim CH. Zedoariae thizoma and curcumin inhibits platelet-derived growth factor-induced proliferation of human hepatic myofibroblasts. Int Immunopharmacol 2005; 5:555-69.
8. PHY906. PhytoCeutica, Inc Botanical Medicines: Oncology Drugs from the 21st Century.
9. Saif MW, Liu S, Elfiky A, Jiang Z, Cheng Y. Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:15116.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
11. A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma. www.ClinicalTrials.gov.